Liraglutide
- Generic Name
- Liraglutide
- Brand Names
- Saxenda, Victoza, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 204656-20-2
- Unique Ingredient Identifier
- 839I73S42A
- Background
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining...
- Indication
Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years ol...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- University of Athens
- Target Recruit Count
- 60
- Registration Number
- NCT03010683
- Locations
- 🇬🇷
''Attikon'' University General Hospital, Athens, Attiki, Greece
Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2023-03-14
- Target Recruit Count
- 40
- Registration Number
- NCT03011021
- Locations
- 🇨🇳
Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2020-03-18
- Target Recruit Count
- 20
- Registration Number
- NCT03011008
- Locations
- 🇨🇳
Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 296
- Registration Number
- NCT02973321
- Locations
- 🇷🇺
Investigational Site Number 6430003, Saratov, Russian Federation
🇷🇺Investigational Site Number 6430001, St-Petersburg, Russian Federation
🇷🇺Investigational Site Number 6430005, Voronezh, Russian Federation
In-market Utilisation of Liraglutide Used for Weight Management in Europe
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 316
- Registration Number
- NCT02967757
- Locations
- 🇮🇹
Novo Nordisk Investigational Site, Siena, Italy
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
- Conditions
- Interventions
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 303
- Registration Number
- NCT02964247
- Locations
- 🇦🇪
Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
- Conditions
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 282
- Registration Number
- NCT02963935
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Arlington, Virginia, United States
Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes
- First Posted Date
- 2016-11-10
- Last Posted Date
- 2023-08-01
- Target Recruit Count
- 24
- Registration Number
- NCT02960659
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Safety and Efficacy of Liraglutide in Parkinson's Disease
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 63
- Registration Number
- NCT02953665
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
Saxenda: Underlying Mechanisms and Clinical Outcomes
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 28
- Registration Number
- NCT02944500
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center General Clinical Research Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.